Journal
CELL BIOLOGY INTERNATIONAL
Volume 33, Issue 4, Pages 466-474Publisher
WILEY
DOI: 10.1016/j.cellbi.2008.07.023
Keywords
Glioma; Mesenchymal stem cell; Adenoviral vector; Interleukin-18
Categories
Funding
- Natural Science Found of China [30270491, 30500526]
- Funds for Key Sci-tech Research Projects of Guangdong Province
- PLA of P.R. China [01Z054]
Ask authors/readers for more resources
Glioma is the most common primary intracranial malignant tumor. Despite advances in surgical techniques and adjuvant radio-and chemotherapies, the prognosis for patients with glioma remains poor. We have explored the effects of using genetically modified mesenchymal stem cells (MSCs) to treat malignant glioma in rats. Mesenchymal stem cells isolated from Sprague-Dawley rats can directly suppress the growth of C6 cells in vitro. MSCs transplanted intratumorally can also significantly inhibit the growth of glioma and prolong survival in C6 glioma-bearing models. MSCs producing Interleukin-18 infected by adenoviral vector inhibited glioma growth and prolonged the survival of glioma-bearing rats. Transplantation of IL-18 secreting MSCs was associated with enhanced T cell infiltration and long-term anti-tumor immunity. Thus, IL-18 may be an effective adoptive immunotherapy for malignant glioma. When used in conjunction with MSCs as targeting vehicles in vivo, IL-18 may offer a promising new treatment option for malignant glioma. (C) 2008 Published by Elsevier Ltd on behalf of International Federation for Cell Biology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available